
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Plant Health Care Plc | LSE:PHC | London | Ordinary Share | GB00B01JC540 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.02 | -0.53% | 3.75 | 3.72 | 3.78 | 3.98 | 3.70 | 3.98 | 2,395,356 | 16:35:02 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pesticides, Agric Chems, Nec | 11.77M | -9.48M | -0.0278 | -1.33 | 12.64M |
Date | Subject | Author | Discuss |
---|---|---|---|
04/5/2023 15:55 | NASDAQ just isn't an option for a small company like PHC Victoria. OTC maybe. Anyway tree shake over and up 14% today as market focuses on the possible buy out price by existing or new investors. | ![]() callumross | |
04/5/2023 12:38 | As a long-term shareholder (since 2020 and keen to stay with the company for at least the next 3 years) I'd support a shift of our primary listing to NASDAQ, given that a growing share of PHC's income and growth over the next 5 years lies in the Western Hemisphere, much of the executive team is already based in the US, and I believe US investors are more likely to recognise the prospective value in the company. I'd also support looking at royalty financing as a potential source of non-dilutive capital, especially for acquisitions and other growth strategies. Royalty finance also avoids the continual refinancing risk associated with funding growth via borrowing. It seems a much commoner and well-established route in the US and Canada than over here, which is another reason for re-basing the company on NASDAQ. Sad, because I value the IHT benefits of AIM shareholdings! | victoriar1 | |
03/5/2023 10:41 | Yes,hurrah for PHC. | ![]() geraldus | |
03/5/2023 10:17 | There's a post on LSE (bots) which may help - sorry for cross post -------------------- Reply from the company Just to let you know that I've received a communication from the company which may allay fears that the company will be sold on the cheap. I’m not prepared to give details, however the following is a direct quote “Please be assured that we have no intention of selling PHC on the cheap, after all this hard work. We are currently canvassing opinion amongst shareholders on the way forwards and will let you [meaning investors] know which way the Board decides to go.” That's a relief - I'm now more positive about the future and the brilliant results. Well done PHC! | ![]() pretax2 | |
03/5/2023 08:22 | Collecting my thoughts here to give the company the benefit of my wisdom. Did not expect the weakness this morning. Are people looking at a bid? If I have the time need to see how Croda got on with PIM. Obvious synergies with LatAm soya but not sure if Croda would know what to do with WEllis. | ![]() cerrito | |
02/5/2023 16:48 | As part of this process, the Board intends to consult with shareholders as to whether AIM remains the right capital market for Plant Health Care to achieve its ambitions. Shareholders are invited to submit their views on this issue to the Chairman by email.Good luck | ![]() oapknob1 | |
02/5/2023 15:35 | Yep- Well done everybody. Treeshake stickers all ‘round. | ![]() pretax2 | |
02/5/2023 15:02 | Mark Watson-Mitchell raving about them on UK Investor Magazine as a great buying opportunity - and I have to agree. | ![]() geraldus | |
02/5/2023 12:45 | So that’s 1% shares traded, buys and sells included and 18% down. Over-reaction perhaps? You’re not getting my stock. 😏 | ![]() pretax2 | |
02/5/2023 12:43 | Wait to see LR trades appear. Be better idea then | ![]() oapknob1 | |
02/5/2023 12:11 | Is the volume large enough to suggest that? | ![]() davemac3 | |
02/5/2023 11:52 | Board already made up their minds. RNS deliberately tanked the share price so TR1 holders aligned with the Board can hoover up, and get the votes to push through their agenda.Now they are pushing the pump button | ![]() oapknob1 | |
02/5/2023 10:07 | hxxps://ukinvestorma | ![]() callumross | |
02/5/2023 08:14 | That’s possible like Spectral MD who I think are reversing into a SPAC already on Nasdaq but still very expensive to do. | ![]() remslie | |
02/5/2023 08:06 | Not sure I completely understand the wobble here. “The board is mindful of the impact to existing shareholders of any potential future equity raise at current share price levels” Says the non-exec chairman, a man who holds more that 1% of the company’s shares, many in an ISA. Seems clear to me they’re trying to improve the status of the company whilst protecting shareholders. ‘If’ a reverse takeover occurs, this would by a quick and less expensive way to list on an exchange. It also increases liquidity (currently lacking for PHC) and increases the share price | ![]() pretax2 | |
02/5/2023 07:50 | Means nothing if they delist. No wonder they weren't doing a presentation on InvestorMeet platform for these results. PI's totally shafted | ![]() oapknob1 | |
02/5/2023 07:48 | On cash, Cenkos are projecting positive cash balances for this year and slightly more than their previous numbers and an increase in cash at end 2024 and major increase in 2025. | ![]() sidam | |
02/5/2023 07:46 | Bailed. Shocking way to treat PI's. No trust in this Board. Shame. Good company with great prospects. Capital better elsewhere.Good luck if still holding. Either be taken private and delist or rto onto US listing.Watching from side now. | ![]() oapknob1 | |
02/5/2023 07:42 | If Cenkos are correct, the fall in the share price appears ridiculous. They have reduced 2024 revenues by about 10% and projected a small profit. For 2025 the look for a PER of less than 3 at the current price and have a target of 37p. So, assuming Cenkos are correct and the share price is 9p, the shares will be profitable in the then current year and stand at next year’s PER of 3 when it is projected to still be growing at 30% for the next few years. I think their target is too low, but this could be a superb buying opportunity. The only problem appears to be the “consultation& | ![]() sidam | |
02/5/2023 07:35 | My guess is Nasdaq far too expensive, takeover does not crystallise value at this level even at a significant premium so going private with a large trade or private equity fund taking a minority stake the most likely. The alternative is to have another fund raise which would be unwelcome at these prices to fund growth. My sense is that any private option would include an offer to take out the smaller stockholders who did not want to lose liquidity which would be funded by the new shareholder. This might be combined with a convertible bond with a conversion price at a significant premium to avoid the dilution. It depends though on the large shareholders agreeing to go private. I suspect the management are trying to avoid taking on short term debt as the costs and risks would be prohibitive before they are clearly profitable. Who knows but not sure the statement is good for sentiment and would have been better to draft behind close doors prior to this vague announcement. | ![]() remslie | |
02/5/2023 07:27 | Possible reverse into a listed US. specialist likely. | ![]() geraldus | |
02/5/2023 07:18 | Well that announcement hasn’t helped “the share price performance” | ![]() davemac3 | |
02/5/2023 07:08 | Not sure what the options are? Nasdaq, private, takeover? | ![]() davemac3 | |
02/5/2023 07:06 | Cenkos upped target price to 37p but no mention of the consultation. | ![]() geraldus |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions Support: +44 (0) 203 8794 460 | support@advfn.com |
ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil |
ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico |
ADVFN France ADVFN US ADVFN Korea |